-
公开(公告)号：EP2920209A1
公开(公告)日：2015-09-23
申请号：EP13789492.9
申请日：2013-11-12
申请人： BioNTech AG , Ganymed Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , TÜRECI, Özlem , STADLER, Christiane , HOLLAND, Julia , BÄHR-MAHMUD, Hayat , BEISSERT, Tim , PLUM, Laura , LE GALL, Fabrice , JENDRETZKI, Arne , FIEDLER, Markus
IPC分类号： C07K16/28
摘要： The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor- associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
公开(公告)号：EP3027208A1
公开(公告)日：2016-06-08
申请号：EP14750331.2
申请日：2014-07-30
申请人： Biontech AG , GANYMED Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , TÜRECI, Özlem , WALTER, Korden , WAGNER, Meike , KREUZBERG, Maria , HÄCKER, Sabine , JACOBS, Stefan
IPC分类号： A61K39/395 , A61K47/48 , G01N33/50 , G01N33/569 , G01N33/574
摘要： The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
-
3.发明公开THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER 审中-公开随着对癌症紧密连接蛋白18.2的治疗抗体治疗
公开(公告)号：EP2976360A1
公开(公告)日：2016-01-27
申请号：EP14714586.6
申请日：2014-03-17
申请人： Ganymed Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , TÜRECI, Özlem
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
摘要： The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
-
4.发明公开CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES 审中-公开CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
公开(公告)号：EP3126381A1
公开(公告)日：2017-02-08
申请号：EP15712657.4
申请日：2015-03-30
申请人： Biontech Cell&Gene Therapies GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Ganymed Pharmaceuticals AG
发明人： SAHIN, Ugur , TÜRECI, Özlem , SIMON, Petra , OMOKOKO, Tana , HOFF, Holger , VOSS, Ralf-Holger , BREITKREUZ, Andrea , HOBOHM, Kathleen , MROZ, Karolina, Anna
IPC分类号： C07K14/725 , C07K14/47 , A61P35/00 , A61K35/26
CPC分类号： C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K14/70521 , C07K14/70539 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/30 , G01N33/505 , G01N33/56972 , G01N33/574
摘要： The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
摘要翻译： 本发明提供了可用于免疫治疗的紧密连接蛋白-6特异性免疫受体（T细胞受体和人工T细胞受体（嵌合抗原受体; CAR））和T细胞表位。
-
公开(公告)号：EP3254695A1
公开(公告)日：2017-12-13
申请号：EP17171169.0
申请日：2013-05-21
申请人： GANYMED Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , TÜRECI, Özlem , MITNACHT-KRAUS, Rita , JACOBS, Stefan, Denis , UTSCH, Magdalena, Jadwiga , HEINZ, Cornelia, Adriana, Maria , STADLER, Christiane, Regina
IPC分类号： A61K39/395 , C07K16/30 , A61K45/06
摘要： The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
-
6.发明授权COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER 有权克劳丁18.2治疗癌症涉及抗体的联合治疗
公开(公告)号：EP2852408B1
公开(公告)日：2017-05-17
申请号：EP13724523.9
申请日：2013-05-21
申请人： Ganymed Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , TÜRECI, Özlem , MITNACHT-KRAUS, Rita , JACOBS, Stefan, Denis , UTSCH, Magdalena, Jadwiga , HEINZ, Cornelia, Adriana, Maria , STADLER, Christiane Regina
IPC分类号： A61K39/395 , C07K16/30 , A61K45/06
CPC分类号： A61K39/39558 , A61K45/06 , C07K16/30 , C07K16/3046 , A61K2300/00
-
公开(公告)号：EP3049065A1
公开(公告)日：2016-08-03
申请号：EP13773604.7
申请日：2013-09-26
申请人： BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人： SAHIN, Ugur , HAAS, Heinrich , KREITER, Sebastian , HÜSEMANN, Yves , DIKEN, Mustafa , REUTER, Kerstin , HEFESHA, Hossam
IPC分类号： A61K9/127 , A61K48/00 , A61K9/50 , A61K31/663
CPC分类号： A61K39/39 , A61K9/1271 , A61K9/1277 , A61K9/5073 , A61K31/675 , A61K39/0011 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/572 , C12N15/88 , C12N2810/10
摘要： The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
-
公开(公告)号：EP3027203A1
公开(公告)日：2016-06-08
申请号：EP14747589.1
申请日：2014-07-30
申请人： BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , PARET, Claudia , VORMBROCK, Kirsten , BENDER, Christian , SIMON, Petra , HARTMANN, Christoph , HUBICH, Stefanie , BUKUR, Thomas , LITZENBERGER, Thorsten
IPC分类号： A61K39/00 , A61K31/7105 , C07K14/47 , C12Q1/68 , G01N33/574
摘要： The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
-
公开(公告)号：EP2917350A1
公开(公告)日：2015-09-16
申请号：EP13792854.5
申请日：2013-11-07
申请人： BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人： SAHIN, Ugur , BEISSERT, Tim , POLEGANOV, Marco , HERZ, Stephanie , KOSTE, Lars
CPC分类号： C12N5/0696 , C12N2501/24 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2501/65 , C12N2501/727 , C12N2506/1307 , C12N2510/00
摘要： The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
-
公开(公告)号：EP2240572B1
公开(公告)日：2015-02-11
申请号：EP08861423.5
申请日：2008-12-12
申请人： BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人： SAHIN, Ugur , POLEGANOV, Marco , BEISSERT, Tim
IPC分类号： C12N5/071
CPC分类号： C12N5/0696 , C12N2510/00
-
-
-
-
-
-
-
-
-
搜索结果
199 条记录 (耗时 0.036 秒)
